National and Kapodistrian University of Athens
Συσχέτιση των πολυμορφισμών του γονιδίου της θυμιδιλικής συνθάσης και των μεταλλάξεων των γονιδίων KRAS και BRAF, με τα κλινικά χαρακτηριστικά ασθενών με ορθοκολικό καρκίνο που λαβαίνουν χημειοθεραπεία με φλουοροπυριμιδίνες
Abstract
dc:descriptionThe polymorphisms of the thymidylate synthase (TYMS) gene and the KRAS/BRAF mutations have been investigated for their prognostic value in colorectal cancer (CRC) in order to identify patients who will benefit from the administered chemotherapy and to tailor treatment decisions. This study investigated the potential prognostic value of TYMS polymorphisms and KRAS or BRAF mutations (mKRAS and mBRAF respectively) in colorectal cancer patients receiving fluoropyrimidine chemotherapy adjuvant or for metastatic disease. For this purpose the genotype of TYMS, KRAS and BRAF was studied in 130 primary colorectal carcinomas of patients receiving adjuvant chemotherapy and in 88 patients receiving chemotherapy for metastatic disease. In respect to TYMS genotype, all known polymorphisms of 3’ and 5’ UTR (untranslated region) were analyzed, including G>C SNP (single nucleotide polymorphisms) and LOH (loss of heterozygosity). Polymorphisms of TYMS gene in each of the 3’ UTR and 5’ UTR were classified into three groups according to the probability for high, medium and low TYMS expression (and similar levels of risk), taking into account evidence from previous studies. For patients receiving adjuvant chemotherapy for colorectal cancer, univariate analysis showed that only ins/LOH polymorphism had a statistically significant effect on survival. Based on this finding, 3’ UTR polymorphisms were allocated into two groups depending on the presence or not of ins/LOH. In patients treated with adjuvant chemotherapy based on fluoropyrimidines, the group of 5’ UTR polymorphisms with a predicted medium expression profile (2RG/3RG, 2RG/LOH, 3RC/LOH) and the absence of the 3’ UTR polymorphism ins/LOH, associated independently with decreased risk of both recurrence and death. The mBRAF was associated independently with increased risk of death, whereas mKRAS not. For patients with mCRC (metastatic CRC) treated with fluoropyrimidine-based chemotherapy, 3’ UTR polymorphisms that include del allele alone (del/del) emerged as independent positive prognostic markers of survival, whereas 5’ UTR polymorphisms not. mKRAS associated independently with a high risk of disease progression. Combination of chemotherapy that included irinotecan was associated with a lower risk of disease progression and death.In conclusion, TYMS polymorphisms were associated with survival of patients with CRC receiving fluoropyrimidine-based chemotherapy in the adjuvant or metastatic setting. For this reason, future prospective studies looking for prognostic and predictive factors should include these polymorphisms in the biomarker group selected for multivariate analysis, in order to develop a predictive and prognostic model that will guide the personalized treatment for patients with colorectal cancer.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ntavatzikos, Anastasios
- Νταβατζίκος, Αναστάσιος
Subjects
dc:subject × 27- Ορθοκολικός καρκίνος
- Ένζυμα κύκλου συνθάσης θυμιδυλικού
- 3' μη μεταφραζόμενη περιοχή
- 5' μη μεταφραζόμενη περιοχή
- Γονίδια, Πολυμορφισμοί
- 5-φλουορουρακίλη
- Πρόγνωση επιβίωσης
- Επιβίωση
- Επικουρική χημειοθεραπεία
- Απώλεια ετεροζυγωτίας
- Μεταστάσεις
- Colorectal cancer
- Thymidylate synthase (TYMS)
- Untranslated regions
- 5-Fluorouracil
- KRAS
- BRAF
- Prognosis - survival
- Adjuvant chemotherapy
- Metastases
- Loss of heterozygosity
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Κλινική Ιατρική
- Medical and Health Sciences
- Basic Medicine
- Clinical Medicine
Rights
dc:rights- Statement dc:rights
-
- BY_NC
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46360